Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-05-05 DOI:10.1158/2643-3230.BCD-24-0274

Camila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, Noemi Puig, Maria-Teresa Cedena, Catarina Maia, Amagoia Mañu, Natalia Gordillo, Oihane Churruca, Diego Alignani, Sarai Sarvide, Iria Vazquez, Cristina Perez, Albert Oriol, Laura Rosinol, Rafael Ríos-Tamayo, Marta-Sonia Gonzalez-Perez, Ana-Pilar Gonzalez-Rodriguez, Felipe de Arriba, Jose M Moraleda, Jesus Martin, Luis Palomera, Valentin Cabañas, Maria-Jose Calasanz, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joan Bladé, Juan-Jose Lahuerta, Jesus F San-Miguel, Bruno Paiva

引用次数: 0

Abstract

Significance: SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.

查看原文本刊更多论文

造血祖细胞突变的动态与多发性骨髓瘤的临床结果无关。

意义：多发性骨髓瘤患者发生SPMs对生存有不利影响。CH患者可能有发展为SPMs的风险，可通过个体化治疗来避免。然而，我们的研究结果表明，筛查chat诊断的效用有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.